Residual Neuromuscular Blockade in Cardiac Surgery Patients
Residual Neuromuscular Blockade
About this trial
This is an interventional diagnostic trial for Residual Neuromuscular Blockade focused on measuring Residual neuromuscular blockade, Reversal, Cardiac surgery
Eligibility Criteria
Inclusion Criteria:
- All outpatients >18 years of age scheduled for elective coronary artery bypass graft surgery (CABG), aortic valve replacement (AVR), or combination CABG/AVR
Exclusion Criteria:
- Chronic kidney disease stage IV or V
- Liver disease, defined as AST, ALT or ALP > 1.5x upper limit of normal Inpatient status
- Allergy to rocuronium
Sites / Locations
- Henry Ford Health Systems
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
No Intervention
Sugammadex
Neostigmine/glycopyrrolate
No reversal administered
Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
No reversal administered at the end of the case